Brief: Rocket Pharmaceuticals Announces FDA Has Lifted The Clinical Hold On The Pivotal Phase 2 Trial Of Rp-A501 For The Treatment Of Danon Disease
20/08/2025 13:46
Aug 20 (Reuters) - Rocket Pharmaceuticals Inc RCKT.O: ROCKET PHARMACEUTICALS ANNOUNCES FDA HAS LIFTED THE CLINICAL HOLD ON THE PIVOTAL PHASE 2 TRIAL OF RP-A501 FOR THE TREATMENT OF DANON DISEASE ROCKET PHARMACEUTICALS INC - FDA AUTHORIZES STUDY RESUMPTION WITH RECALIBRATED DOSE ROCKET PHARMACEUTICALS- TO WORK WITH INVESTIGATORS TO IMPLEMENT IMMUNOMODULATORY REGIMEN MORE CLOSELY REFLECTING GIVEN IN PHASE 1 PEDIATRIC COHORT Source text: ID:nBwh5DPfa Further company coverage: RCKT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket Pharmaceuticals
See all newsRocket Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Rocket Pharmaceuticals posts Q2 profit helped by PRV sale
Brief: Rocket Pharmaceuticals Q2 EPS USD 1.08